- Home
- TEVA
as 12-20-2024 3:43pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 19.2B | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 11.6M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.34 - $22.17 | Next Earning Date: | 01-29-2025 |
| Revenue: | $16,772,000,000 | Revenue Growth: | 9.81% |
| Revenue Growth (this year): | 4.7% | Revenue Growth (next year): | 4.47% |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
Insider Monkey
6 hours ago
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
GlobeNewswire
21 hours ago
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Zacks
a day ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Motley Fool
a day ago
My Top 10 Portfolio Holdings for 2025
TipRanks
2 days ago
Teva price target raised to $28 from $26 at UBS
Insider Monkey
3 days ago
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
MT Newswires
3 days ago
Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says
MT Newswires
3 days ago
BofA Securities Raises Price Target on Teva Pharmaceutical Industries to $25 From $23, Keeps Buy Rating
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.